4//SEC Filing
Cormorant Asset Management, LP 4
Accession 0000929638-25-000822
CIK 0001774857other
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 4:02 PM ET
Size
11.7 KB
Accession
0000929638-25-000822
Insider Transaction Report
Form 4
Transactions
- Conversion
Common Stock
2025-02-14+800,189→ 800,189 total(indirect: See Footnote) - Purchase
Common Stock
2025-02-14$16.00/sh+187,500$3,000,000→ 987,689 total(indirect: See Footnote) - Conversion
Series C Convertible Preferred Stock
2025-02-14−6,780,810→ 0 total(indirect: See Footnotes)→ Common Stock (800,189 underlying)
Chen Bihua
Other
Transactions
- Conversion
Common Stock
2025-02-14+800,189→ 800,189 total(indirect: See Footnote) - Purchase
Common Stock
2025-02-14$16.00/sh+187,500$3,000,000→ 987,689 total(indirect: See Footnote) - Conversion
Series C Convertible Preferred Stock
2025-02-14−6,780,810→ 0 total(indirect: See Footnotes)→ Common Stock (800,189 underlying)
Footnotes (3)
- [F1]Upon the closing of the Issuer's initial public offering of Common Stock on February 14, 2025, the Series C Convertible Preferred Stock automatically converted into Common Stock at a 1-for-8.474 conversion ratio, after giving effect to a reverse stock split effected by the Issuer on February 5, 2025, for an aggregate of 800,189 shares of Common Stock. The Series C Convertible Preferred Stock had no expiration date.
- [F2]Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and Cormorant Private Healthcare Fund V, LP ("Fund V"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as general partner of the Master Fund, and Cormorant Private Healthcare V GP, LLC ("GP V LLC") serves as general partner of Fund V. Bihua Chen serves as the managing member of GP LLC, GP V LLC and the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
- [F3]Represents 298,486 and 689,203 shares of Common Stock beneficially owned by the Master Fund and Fund V, respectively.
Documents
Issuer
Aardvark Therapeutics, Inc.
CIK 0001774857
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001583977
Filing Metadata
- Form type
- 4
- Filed
- Feb 18, 7:00 PM ET
- Accepted
- Feb 19, 4:02 PM ET
- Size
- 11.7 KB